Suppr超能文献

在无明显基因突变的头颈部鳞状细胞癌中p53蛋白的过表达。

Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations.

作者信息

Xu L, Chen Y T, Huvos A G, Zlotolow I M, Rettig W J, Old L J, Garin-Chesa P

机构信息

Ludwig Institute for Cancer Research, New York Unit, Memorial Sloan-Kettering Cancer Center, NY 10021.

出版信息

Diagn Mol Pathol. 1994 Jun;3(2):83-92. doi: 10.1097/00019606-199406000-00004.

Abstract

Structural alterations of p53 and overexpression of the p53 protein are found in a large proportion of human cancers. In this study, we examined the frequency of p53 mutations and p53 overexpression in squamous cell carcinomas (SQCC) of head and neck. Expression of p53 was detected by immunochemistry (IHC) with monoclonal antibodies defining three distinct epitopes: PAb421 (species cross-reactive epitope on normal and mutated p53), PAb1801 (epitope on normal and mutated human p53), and PAb240 (conformational epitope of mutated p53 and denatured normal p53). Genetic alterations of p53 were identified by single-strand conformational polymorphism (SSCP) analysis and DNA sequencing in selected cases. IHC assays revealed nuclear p53 immunostaining in 53% of cases (32 of 60) with PAb1801, 38% (23 of 60) with PAb421, and 32% (19 of 60) with PAb240. Cases positive with PAb421 or PAb240 were also positive with PAb1801, whereas PAb421 and PAb240 identified overlapping but distinct tumor subsets. Areas of carcinoma in situ present in the tumor specimens showed nuclear p53 immunostaining in 11 of 26 cases. SSCP analysis for exons 5-9, the most common sites of p53 abnormalities, revealed mutations in 26% (15 of 58) of the evaluable cases. Comparison of the SSCP results with the IHC results for PAb1801 identified 11 cases that were positive by both methods, 4 cases with p53 mutations that were negative by IHC, 20 cases positive by IHC but without detectable p53 mutations, and 23 cases negative by both methods. IHC with PAb240, which is thought to be specific for mutated p53, was positive in 9 cases with demonstrable p53 mutations and in 9 cases with no detectable mutations. DNA sequence analysis of nine tumors identified point mutations, nonsense mutations, and frame-shift mutations. In conclusion, our study shows that p53 overexpression in SQCC of head and neck as detected by IHC is a frequent finding, and that overexpression is associated with common types of p53 mutations in some cases. However, IHC identifies p53 overexpression in some tumors with apparently normal SSCP patterns and, conversely, tumors with nonsense or frameshift mutations may not express any p53 detectable by IHC.

摘要

在大部分人类癌症中都发现了p53的结构改变以及p53蛋白的过表达。在本研究中,我们检测了头颈部鳞状细胞癌(SQCC)中p53突变和p53过表达的频率。通过免疫化学(IHC)使用定义三个不同表位的单克隆抗体检测p53的表达:PAb421(正常和突变p53上的种属交叉反应表位)、PAb1801(正常和突变人p53上的表位)以及PAb240(突变p53和变性正常p53的构象表位)。在选定病例中通过单链构象多态性(SSCP)分析和DNA测序鉴定p53的基因改变。免疫组化分析显示,使用PAb1801时,53%(60例中的32例)的病例出现核p53免疫染色;使用PAb421时,38%(60例中的23例)出现;使用PAb240时,32%(60例中的19例)出现。PAb421或PAb240阳性的病例使用PAb1801时也呈阳性,而PAb421和PAb240鉴定出重叠但不同的肿瘤亚组。肿瘤标本中存在的原位癌区域在26例中有11例显示核p53免疫染色。对p53异常最常见的位点外显子5 - 9进行SSCP分析,在58例可评估病例中有26%(15例)发现突变。将SSCP结果与PAb1801的免疫组化结果进行比较,发现11例两种方法均为阳性,4例p53突变但免疫组化呈阴性,20例免疫组化阳性但未检测到p53突变,23例两种方法均为阴性。认为对突变p53具有特异性的PAb240免疫组化在9例有可证实p53突变的病例和9例未检测到突变的病例中呈阳性。对9个肿瘤进行DNA序列分析发现了点突变、无义突变和移码突变。总之,我们的研究表明,通过免疫组化检测到头颈部鳞状细胞癌中p53过表达是常见现象,并且在某些情况下过表达与常见类型的p53突变相关。然而,免疫组化在一些SSCP模式明显正常的肿瘤中鉴定出p53过表达,相反,有无义或移码突变的肿瘤可能不表达免疫组化可检测到的任何p53。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验